NICOLE VITULLO
CIK 1196863 · last filed 2025-06-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$146.56M
Companies
23
Total Filings
108
Lifetime Open-Market Net
$61.17M
Filer Profile
Reported Address
3533 SAWMILL ROADNEWTOWN SQUARE, PA 19073
Related Filers
JAMES C BLAIR — 198 joint filings, latest 2019-08-08
BRIAN H DOVEY — 198 joint filings, latest 2019-08-08
JESSE I TREU — 197 joint filings, latest 2019-08-08
KATHLEEN K SCHOEMAKER — 147 joint filings, latest 2015-08-20
Brian K Halak — 123 joint filings, latest 2019-08-08
PARTERS VII L P DOMAIN — 42 joint filings, latest 2019-08-08
Domain Partners VI, L.P. — 40 joint filings, latest 2017-12-13
DP VI Associates, L.P. — 35 joint filings, latest 2017-12-13
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. (ESPR) Delisted | Director | 36,918 | $3.18 | $117.4K | $1.97M | 17 | 2025-06-02 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Director | 6,442 | $0.55 | $3.5K | -$67.4K | 14 | 2022-02-07 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | Director | 0 | — | — | -$5.96M | 21 | 2020-01-29 |
| Vyome Holdings, Inc (OBLN) Delisted | 10%+ Owner | 1,328,657 | $9.15 | $12.16M | $0 | 1 | 2016-10-14 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | 10%+ Owner | 2,024,203 | — | — | -$6.47M | 1 | 2016-08-03 |
| Celator Pharmaceuticals Inc (CPXX) Delisted | Director | 0 | — | — | $0 | 2 | 2016-07-12 |
| Evoke Pharma Inc (OMED) Delisted | 10%+ Owner | 625,289 | — | — | -$9.70M | 2 | 2016-05-27 |
| SNDX | 10%+ Owner | 761,062 | $18.07 | $13.75M | $0 | 1 | 2016-03-08 |
| Tobira Therapeutics, Inc. (TBRA) Delisted | 10%+ Owner | 38,094 | — | — | $0 | 1 | 2015-05-06 |
| Evofem Biosciences, Inc. (NEOT) Delisted | 10%+ Owner | 8,292 | — | — | $0 | 2 | 2014-12-10 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | 22,306 | — | — | $7.06M | 2 | 2014-11-18 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 33,890 | — | — | $0 | 1 | 2014-03-17 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | 10%+ Owner | 3,019,312 | — | — | $12.57M | 12 | 2014-02-14 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | 10%+ Owner | 1,752,707 | $38.22 | $66.99M | $0 | 1 | 2014-02-04 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 3,585 | $5.54 | $19.9K | $3.97M | 4 | 2014-01-17 |
| TNDM | 10%+ Owner | 318,906 | $17.62 | $5.62M | $0 | 1 | 2013-11-19 |
| VCYT | 10%+ Owner | 3,063,294 | $41.52 | $127.19M | $0 | 1 | 2013-11-04 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | 10%+ Owner | 47,835 | — | — | $3.00M | 1 | 2013-08-28 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 47,963 | — | — | $8.00M | 1 | 2013-07-16 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | 10%+ Owner | 296,742 | — | — | $18.29M | 12 | 2011-12-22 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 35,388 | $0.08 | $2.9K | $12.11M | 1 | 2011-11-21 |
| ZOGENIX, INC. (ZGNX) Delisted | 10%+ Owner | 1,240,417 | $26.68 | $33.09M | $16.40M | 2 | 2011-09-20 |
| Volcano Corp (VOLC) Delisted | 10%+ Owner | 61,860 | — | — | $0 | 2 | 2008-06-09 |
Recent Filings · Page 6 of 11
108 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-11-18 | Durata Therapeutics, Inc. (DRTX) Delisted | Disp (D) | — | $0 | EDGAR |
| 2014-10-01 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-09-11 | ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | Other (J) | −1,099,005 | $0 | EDGAR |
| 2014-08-07 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Conv (C) | +102,000 | $0 | EDGAR |
| 2014-03-21 | — | Disp (D) | −10,442,531 | -$146.20M | |
| 2014-03-17 | Achaogen, Inc. (AKAO) Delisted | Conv (C) | +2,020,939 | $0 | EDGAR |
| 2014-02-14 | CADENCE PHARMACEUTICALS INC (CADX) Delisted | Mixed | +4,210,416 | -$78 | EDGAR |
| 2014-02-04 | Dicerna Pharmaceuticals Inc (DRNA) Delisted | Conv (C) | +1,765,711 | $0 | EDGAR |
| 2014-01-17 | ALIMERA SCIENCES INC (ALIM) Delisted | Sell (S) | −19,440 | -$124.2K | EDGAR |
| 2013-12-19 | ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.